Roche Innovation Center Copenhagen A/S is the home of RNA Therapeutics Research (RTR) for Roche Pharma Research and Early Development (pRED).

Roche Innovation Center Copenhagen, (formerly Santaris Pharma A/S) is a leader in the rapidly emerging field of RNA-targeted drugs, where it is exploiting its proprietary Locked Nucleic Acid (LNA) platform to discover important novel medicines across multiple therapeutic areas.  Drugs directed against RNA targets have the potential to transform human medicine, making drug discovery, development and manufacture more efficient, faster and less error prone than ever before. At the same time, this novel class of drugs offers the means to address disease targets that have previously been undruggable with conventional drug therapies such as small molecules or antibodies.

RICC is continuously investing in its drug discovery and technology platform, bringing together a multidisciplinary team of scientists with experience, talent and commitment to deliver broadly on the promise of RNA medicines. The RICC team is headed by Bo Rode Hansen and comprises research groups in chemistry, oligo synthesis, molecular biology, pharmacology, toxicology, PK and bioinformatics.

Recognizing the broad application of RNA medicines across human diseases, RICC is collaborating with selected pharmaceutical companies to discover and develop novel drugs within their therapeutic focus areas. These efforts complement the Drug Discovery efforts within the Roche Group and accelerates the emergence of the new RNA-therapeutic era in human medicine.